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N363S-G allele, GLCCI1-C allele) or decreased GC sen-
sitivity (9β-G allele, ER22/23EK-A/A allele, GLCCI1-T 
allele). Differences in baseline DAS and relative decrease 
in DAS in the different genotype groups were analyzed 
using analysis of covariance and linear regression. Baseline 
DAS was higher in patients who carried polymorphisms of 
the GR and GLCCI1 genes associated with decreased GC 
sensitivity. GLCCI1 genotype, but not GR genotypes, was 
associated with improvement in DAS in male patients with 
RA. The GLCCI1 gene minor allele (rs37972) may be asso-
ciated with less efficient GC bridging therapy in male RA 
patients. Carriers of the BclI-G, N363S-G, or GLCCI1-C 
alleles had lower levels of baseline disease activity, sug-
gesting a role for the GLCCI1 and GR gene in regulation of 
GC sensitivity to endogenously produced cortisol.
Keywords Rheumatoid arthritis · Glucocorticoid 
sensitivity · Glucocorticoid receptor gene polymorphisms · 
Glucocorticoid-induced transcript 1 gene polymorphisms
Abbreviations
GC  Glucocorticoids
RA  Rheumatoid arthritis
GR  Glucocorticoid receptor
GLCCI1  Glucocorticoid-induced transcript 1
DAS  Disease activity score
DMARDs  Disease modifying antirheumatic drugs
SJC  Swollen joint count
RAI  Ritchie Articular Index
ESR  Erythrocyte sedimentation rate
GH  General health at a 100 mm scale
NSAIDs  Non-steroidal anti-inflammatory drugs;
TNF-α  Tumor necrosis factor-alpha
GC-S group  Carriers of BclI (haplotype 1) and/or N363S 
(haplotype 2)
Abstract Glucocorticoids (GC) are widely used in rheu-
matoid arthritis (RA). Ongoing active disease due to GC 
resistance may unfavorably influence long-term disease 
outcome in RA. We studied the association between the 
presence of glucocorticoid receptor (GR) and glucocorti-
coid-induced transcript 1 (GLCCI1) gene polymorphisms, 
which modulate GC sensitivity, and baseline disease activ-
ity score (DAS) and efficacy of GC bridging therapy in 
RA. We prospectively studied in vivo GC sensitivity in 
138 patients with recent-onset or longstanding RA. In vivo 
GC sensitivity was expressed as the relative decrease in 
DAS following 2 weeks of standardized GC therapy. All 
patients were genotyped for the GR polymorphisms BclI 
(rs41423247), N363S (rs6195), 9β (rs6198), ER22/23EK 
(rs6189 + rs6190), and the GLCCI1 variant rs37972 and 
subsequently divided in groups carrying a polymorphism 
associated with increased GC sensitivity (BclI-G allele, 
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GC-I group  Carriers of 9β (haplotype 3) or 
9β + ER22/23EK (haplotype 4)
GC-SS  GC-S group + homozygous carriers of the 
GLCCI1-C wild-type allele
GC-II  GC-I group + carriers of one or two minor 
GLCCI1-T alleles
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease char-
acterized by chronic inflammation of the synovial lin-
ing which ultimately, when left untreated, leads to erosive 
disease of the joints. To date, therapeutic strategies for the 
treatment of recent-onset RA are characterized by initia-
tion of aggressive (combination) therapy in the ‘window of 
opportunity’, as this has been shown to improve long-term 
outcome of RA [1–4]. GCs are frequently prescribed as 
‘bridging’ therapy, referring to the time period needed for 
newly initiated disease modifying antirheumatic drugs 
(DMARDs) to become clinically effective. Recently, we 
have demonstrated that a poor initial response to GC bridg-
ing therapy is a strong predictor for DMARD failure at 
3-months follow-up [5]. These findings underscore the 
importance of the primary response to GC treatment and 
prompted us to further identify determinants of GC sensitiv-
ity. Individual GC sensitivity is highly variable and is deter-
mined by both genetic and acquired factors [6]. In this con-
text, the recent findings of Tantisira and co-workers reveal 
that the functional mutant T allele of SNP rs37972, mapping 
to the glucocorticoid-induced transcript 1 gene (GLCCI1), 
is associated with declined efficacy of GC inhalation ther-
apy in asthmatic patients are of special interest [7]. We 
hypothesized that GLCCI1-mediated differences in clinical 
response to GC may also apply to patients with RA (class 
effect in pharmacogenetics). In addition, four functionally 
well-characterized polymorphisms of the glucocorticoid 
receptor (GR) gene (9β, ER22/23EK, BclI and N363S) that 
modulate GC sensitivity could also partly explain variation 
in clinical response to GC in patients with RA, as has been 
shown in other inflammatory diseases [8–12].
Therefore, the aim of this study was to examine whether 
the presence of polymorphisms of the GR and GLCCI gene 
is associated with disease activity and the clinical effect of 
GC bridging therapy in recent-onset and longstanding RA.
Patients and methods
Patients
This study was embedded in a multicenter randomized 
clinical trial studying persons older than 18 years 
presenting with a recent-onset arthritis, the so-called 
tREACH study (treatment in the Rotterdam early arthri-
tis cohort). The outline of this study has been described 
in detail [13]. All tREACH patients with definite RA 
and disease activity scores before start and after 2 weeks 
of GC treatment were included in the current study 
(N = 112).
In an independent cohort, 26 patients with established 
RA and active disease were recruited (FLARE study). 
Active disease was defined as disease activity requiring GC 
therapy according to the treating rheumatologists [14].
All patients received standardized GC therapy, either 
15 mg prednisone daily or a single intramuscular depot 
of methylprednisolone 120 mg or triamcinolone aceton-
ide 80 mg. All tREACH patients were GC and DMARD 
naive. FLARE patients had not used GC for at least the last 
3 months and were on stable DMARD therapy.
Methods
In vivo glucocorticoid sensitivity
Trained research nurses examined patients before and 
after 2 weeks of standardized GC treatment using a stand-
ardized 44-joint count for swelling and pain. Disease 
activity was objectively scored using the DAS44 with four 
variables [swollen joint count (SJC), Ritchie Articular 
Index (RAI), erythrocyte sedimentation rate (ESR), and 
general health at a 100 mm scale (GH)], hereafter referred 
to as DAS [15]. The relative decrease in DAS (%) [(DAS-
baseline − DASafter 2 weeks)/DASbaseline) × 100] was used as 
an index for in vivo GC sensitivity. Relative improve-
ment of the individual measures of the DAS was calcu-
lated similarly. Use of non-steroidal anti-inflammatory 
drugs (NSAIDs) and, if applicable, use of DMARDs and 
tumor necrosis factor-alpha (TNF-α) blocking agents was 
recorded at baseline.
Glucocorticoid receptor polymorphisms
All 138 patients were genotyped for four functional 
polymorphisms of the GR gene (ER22/23EK, rs6189 
and rs6190; N363S, rs6195; BclI, rs41423247 and 9β, 
rs6198) and the GLCCI1 gene variant (rs37972). DNA 
was extracted from samples of peripheral venous blood 
samples using standard techniques. Genotyping was 
performed using Taqman allelic discrimination assays 
(Applied Biosystems), following protocols described by 
the supplier. Genotyping of BclI failed in one patient, 
in two patients each the N363S, and GLCCI1 genotype 
could not be determined. Results were analyzed using 
the sequence detection system 2.2 software (Applied 
Biosystems).
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Statistical analysis
Differences between groups of the baseline characteristics 
were tested using ANOVA or Mann–Whitney U test for 
continuous variables and Pearson’s chi-square test for cat-
egorical variables.
The different GR haplotypes were classified based on 
their known functional associations with GC sensitiv-
ity (Fig. 1). Patients with haplotype 1 (BclI, mutant G 
allele) and 2 (N363S, mutant G allele) were merged and 
referred to as the GC-S (increased GC sensitivity) group 
(N = 72). Patients with haplotype 3 (9β, mutant G allele) 
and 4 (ER22/23EK, mutant alleles A and A + 9β, mutant 
G allele) were combined and referred to as the GC-I 
(decreased GC sensitivity) group (N = 29). Patients who 
carried both haplotype 1/2 and 3/4 were excluded.
In addition, a new genotype variable was composed, 
combining the allele variants of the GR and GLCCI1 genes 
associated with increased and decreased GC sensitivity, 
respectively, (GC-SS: GC-S group + homozygous carriers 
of the GLCCI1-C wild-type allele, N = 30; GC-II: GC-I 
group + carriers of one or two minor GLCCI1-T alleles, 
N = 19).
We used analysis of covariance to analyze baseline DAS 
in carriers and non-carriers of the GR and the GLCCI1 
gene polymorphisms and adjusted for age, gender, and use 
of NSAIDs. Relative decrease in DAS in the different gen-
otype groups was analyzed using linear regression (relative 
decrease in DAS as dependent variable; use of NSAIDs as 
covariate). Male and female patients were analyzed sepa-
rately (significant interaction gender–GLCCI1 genotype).
Differences between individual measures of the DAS 
(SJC, RAI, ESR, and GH) in the different genotype groups 
were analyzed using the Kruskal–Wallis test with post hoc 
Dunn’s correction for multiple comparisons.
All analyses were performed using the statistical pack-
age of SPSS for windows, version 17.0 (Chicago, IL, 
USA) and GraphPad Prism, version 5.01 (La Jolla, CA, 
USA). We considered differences statistically significant if 
p ≤ 0.05 (two-sided).
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Fig. 1  Polymorphisms in the GR and GLCCI1 genes. The GR gene 
consists of nine exons and is located on chromosome 5. The BclI 
(mutant G allele) and N363S (mutant G allele) SNPs have been 
associated with increased GC sensitivity in vivo, whereas the 9β 
(mutant G allele) and the ER22/23EK (GAGAGG → GAAAAG) 
polymorphisms have been linked to decreased GC sensitivity in vivo. 
Rs37972 is located 865 base pairs upstream of exon 1 of the GLCCI1 
gene. The GC-S group consists of all patients with GR haplotype 1 
and/or haplotype 2 and did not carry haplotype 3 or 4. Patients in the 
GC-S group who also carried the wild-type GLCCI1 genotype were 
classified as GC-SS. Patients with GR haplotype 3 or 4, and did not 
carry haplotype 1 or 2, were grouped as GC-I. Patients in the GC-I 
group who also carried one or two mutant GLCCI1-T alleles were 
attributed to the GC-II group
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Ethical approval
All subjects signed informed consent, and the study was 
approved by the medical ethics committee of the Erasmus 
Medical Center.
Results
A total of 138 patients were included in the current study 
of whom 73 patients were treated with oral GC and 65 
patients were given an intramuscular depot of GC. Further 
baseline characteristics of the study population are shown 
in Table 1. The frequencies of the individual GR polymor-
phisms (Table 2) in our cohort were similar to those we 
observed in earlier, larger cohorts [16].
Glucocorticoid receptor and GLCCI1 gene polymorphisms 
and disease activity
The majority of patients had moderately to highly active 
RA (DAS ≥ 2.4, N = 117, 84.8 %). Patients in the GC-I 
(haplotype 3 or 4) and GC-II (GC-I and carrier of one or 
two minor GLCCI1-T alleles) groups and carriers of the 
Table 1  Patients characteristics
DAS44: Disease activity score, 44 joints; anti-CCP: anti-cyclic citrullinated protein
a p < 0.05 compared to established RA, intramuscular GC bridging
b p < 0.05 compared to early RA, intramuscular GC bridging
c Anti-CCP was not routinely analyzed, % is based on 20 patients with known anti-CCP status
d 7 patients were not using any DMARD at time of assessment
Early RA Early RA Established RA
Oral GC bridging  
(N = 73)
Intramuscular GC  
bridging (N = 39)
Intramuscular GC  
bridging (N = 26)
Female gender, N (%) 43 (58.9) 26 (66.7) 16 (61.5)
Age, mean (SD) 54.5 (12.6) 53.3 (15.3) 55.7 (12.1)
Body mass index, median (range) 25.6 (17.5–43.1) 25.5 (20.3–39.2) 25.9 (18.9–40.4)
Disease duration (months), median (range) 5.7 (1.2–11.9)a 4.6 (0.5–11.9)a 67.00 (0–282)
Rheumatoid factor (IgM) positive, N (%) 59 (80.8) 32 (82.1) 20 (76.9)
Anti-CCP positive, N (%) 64 (87.7) 31 (79.5) 18 (90.0)c
Presence of joint erosions, N (%) 5 (6.8)a,b 10 (25.6)a 14 (53.8)
DAS44 at baseline, mean (SD) 3.21 (0.99) 3.25 (0.74) 3.33 (0.98)
Use of NSAID, N (%) 52 (71.2) 27 (69.2) 15 (57.7)
Use of methotrexate, N (%) – – 15 (57.7)
Use of hydroxychloroquine, N (%) – – 7 (26.9)
Use of sulfasalazine, N (%) – – 4 (15.4)
Number of DMARDs, median (range) – – 1 (0–3)d
Use of anti-TNF therapy, N (%) – – 3 (11.5)
Table 2  Frequencies of individual polymorphisms of the GR and GLCCI1 gene
Genotyping of BclI failed in one patient; in two patients each, the N363S and GLCCI1 genotype could not be determined. The BclI polymor-
phism is located in an intron. The 9β SNP is located in an ATTTA motif (ATTTA → GTTTA) and is associated with increased stability of the 
GR-β mRNA and a reduced transrepressive capacity in vitro. The nucleotide change in the ER22/23EK variant results in a different amino acid 
(glutamic acid–arginine → glutamic acid–lysine) and has been related to increased expression of the transcriptionally less active GR-A isoform. 
Similarly, the A to G nucleotide change in the N363S polymorphism alters asparagine into serine. In vitro assays demonstrated reduced lucif-
erase reporter activity in cells transfected with a rs37973 reporter construct. Data are presented as N (%)
Polymorphisms Nucleotide change Wildtype Heterozygous carrier Homozygous carrier
BclI rs41423247 C→G 52 (38) 70 (51.1) 15 (10.9)
9β rs6198 A→G 89 (64.5) 42 (30.4) 7 (5.1)
ER22/23EK rs6189 and rs6190 G→A and G→A 129 (93.5) 8 (5.8) 1 (0.7)
N363S rs6195 A→G 128 (94.1) 8 (5.9) 0 (0)
GLCCI1 rs37973 C→T 53 (39) 63 (46.3) 20 (14.7)
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GLCCI1 mutant T allele all had significantly higher base-
line disease activity than their respective reference geno-
type group or wild-type allele, as expected based upon the 
functional associations of these genotype variants (Fig. 2). 
Use of NSAIDs was also independently associated with 
higher baseline DAS (p < 0.05; data not shown).
Glucocorticoid receptor and GLCCI1 gene polymorphisms 
and response to GC bridging therapy
After 2 weeks of GC bridging therapy, the mean (SD) rela-
tive decrease in DAS in all patients was 30.2 (25.4) %. 
Orally and intramuscularly treated patients displayed sim-
ilar responses (oral GC: 32.0 (21.7) % and intramuscular 
GC: 28.3 (29.0) %). Male and female patients had signifi-
cantly different levels of relative decrease in DAS (men 
38.6 (24.1) %; women 25.1 (24.9) %, p = 0.002). When all 
patients were analyzed together, no trend between GLCCI1 
genotype and relative decrease in DAS was observed 
(Fig. 3a, ptrend = 0.257).
Within men, however, carriers of the mutant GLCCI1-T 
allele had relatively less improvement in DAS as compared 
to patients who only have the wild-type C allele (Fig. 3b, 
ptrend = 0.034). A comparable pattern was observed when 
male patients in the GC-SS and GC-II groups were stud-
ied although this did not reach statistical significance 
(p = 0.056), probably due to small numbers of patients 
(data not shown).
This sexual dimorphic effect of improvement in DAS 
according to GLCCI1 genotype was further explored 
by studying the individual measures of the DAS (SJC, 
RAI, ESR, and GH), as visualized in Fig. 4. The relative 
improvement in SJC was significantly associated with 
GLCCI1 genotype in male patients (Fig. 4a), whereas rela-
tive improvement in RAI, ESR, and GH was not associated 
with GLCCI1 genotype (Fig. 4b–d). Improvement in DAS 
and/or SJC was not associated with GLCCI1 genotype in 
women (Figs. 3c, 4a). Apart from GLCCI1 genotype, rela-
tive improvement in ESR was significantly higher in male 
than in female patients (Fig. 4c). Absolute levels of SJC, 
RAI, ESR, and GH at baseline and after 2 weeks of GC 
bridging therapy are provided in Table 3. Patients with GR 
haplotype 1 or 2 (GC-S) and patients with GR haplotype 
3 or 4 (GC-I) did not differ significantly in their level of 
improvement in DAS after 2 weeks of GC treatment. A 
subsequent subanalysis of men and women separately 
also did not reveal any difference in improvement in DAS 
according to GR genotype status (Fig. 5).
Fig. 2  Baseline DAS in relation to GR and GLCCI1 gene polymor-
phisms. Baseline DAS in GC-S versus GC-I, patients with wild-
type GLCCI1-C alleles versus carriers of the GLCCI1-T variant and 
patients with both the GC-S and GLCCI1-C variant (GC-SS) versus 
patients with both the GC-I and GLCCI1-T variant (GC-II); adjusted 
for age, gender, and use of NSAIDs
Fig. 3  The relative improvement in DAS following GC bridg-
ing therapy in relation to GLCCI1 gene polymorphisms. Percentual 
improvement in DAS after 2 weeks of standardized GC treatment in 
all patients (a) male patients (b) and female patients (c). Error bars 
represent standard error of the mean (SEM); adjusted for use of 
NSAIDs
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Discussion
GCs are widely used in RA and as in other inflammatory 
disorders; GC resistance is a well-known phenomenon 
which may lead to ongoing active disease [6, 17]. Accu-
mulating evidence supports the existence of a ‘window of 
opportunity’ and recent guidelines for treating RA, there-
fore emphasizing the importance of reaching low disease 
activity as soon as possible [18, 19]. In this context, predic-
tion of efficacy of GC bridging therapy is of great value, 
in particular since we have shown that a poor GC response 
after 2 weeks is a strong predictor of DMARD failure at 
3 months [5]. We show for the first time that the GLCCI1 
gene minor allele (rs37972) is associated with higher RA 
disease activity and, in male RA patients, with a lower clin-
ical response to GC bridging therapy.
Individual GC sensitivity is influenced by genetic fac-
tors, cellular GR number, and affinity and GC availability 
[6, 17]. GR polymorphisms have been associated with dif-
ferences in metabolic parameters and body composition, 
Fig. 4  Relative improvement 
of SJC (a) RAI (b) ESR (c) 
and GH (d) in male and female 
patients with RA after 2 weeks 
of GC bridging therapy, 
according to GLCCI1 genotype 
(Tukey box-and-Whisker plot). 
Relative improvement of each 
individual measure of the DAS 
was calculated as 100 × [(base-
line value-2 weeks value)/base-
line value]. In eight patients, the 
relative improvement in RAI 
could not be calculated because 
the baseline value was zero 
(two male CC, two female CC, 
two male CT and, two female 
CT patients). Negative values 
indicate higher levels of SJC/
RAI/ESR/GH after 2 weeks of 
GC bridging therapy as com-
pared to their baseline values. 
SJC = swollen joint count, 
RAI = Ritchie Articular Index, 
ESR = erythrocyte sedimenta-
tion rate, GH = general health 
at a 100 mm scale. Please note 
the different scales on the Y-axis
Table 3  DAS and individual measures of the DAS
Absolute levels of DAS and individual measures of the DAS at baseline and after GC bridging therapy according to GLCCI1 genotype and gen-
der. Individual measures of the DAS are given as median (range)
SJC swollen joint count, RAI Ritchie articular index, ESR erythrocyte sedimentation rate, GH general health at a 100 mm scale
Men Women
CC (N = 22) CT (N = 21) TT (N = 9) CC (N = 31) CT (N = 42) TT (N = 11)
DAS44 at baseline, mean (SD) 2.95 (0.97) 3.62 (1.13) 3.19 (0.73) 2.96 (0.83) 3.42 (0.82) 3.39 (0.92)
 SJC-baseline 7.5 (2–23) 12 (2–25) 8 (2–21) 5 (1–19) 7.5 (1–23) 5 (2–14)
 RAI-baseline 5 (0–19) 6 (0–20) 5 (2–12) 7 (0–15) 7 (0–31) 7 (2–50)
 ESR-baseline 21(1–74) 26.5 (9–76) 16 (3–81) 18 (1–51) 25.5 (5–69) 24 (13–78)
 GH-baseline 45.5 (9–100) 50.0 (5–95) 47 (11–80) 52 (9–91) 59.5 (5–99) 50 (1–83)
DAS44-2 weeks, mean (SD) 1.53 (0.74) 2.47 (1.33) 2.40 (1.02) 2.24 (0.90) 2.50 (0.99) 2.76 (1.29)
 SJC-2 weeks 2.5 (0–7) 5 (2–26) 5 (2–11) 2 (0–12) 3.5 (0–14) 5 (0–12)
 RAI-2 weeks 1 (0–8) 4 (0–32) 3 (0–16) 4 (0–18) 5 (0–25) 7 (0–19)
 ESR-2 weeks 8 (1–55) 13 (1–71) 11 (1–47) 13 (1–42) 15 (2–69) 21 (6–28)
 GH-2 weeks 15 (0–69) 23 (0–100) 40 (2–67) 30 (0–76) 32 (0–100) 30 (2–80)
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susceptibility to and severity of inflammatory diseases, and 
response to GC therapy [8, 9]. In RA, polymorphisms of 
the GR gene associated with reduced (i.e., 9β) or increased 
(i.e., BclI and N363S) GC sensitivity are associated with 
increased and decreased susceptibility, respectively, to RA. 
Moreover, patients using TNF-α blocking agents more 
frequently carried the ER22/23EK variant [16]. Increased 
expression of the transcriptionally less active GR-A 
(translational) isoform due to the ER22/23EK polymor-
phism might be one of the underlying mechanisms of GC 
resistance [10]. GC resistance in association with the 9β 
polymorphism might be related to increased stability of the 
GRβ mRNA (which in turn may lead to higher levels of the 
dominant negative GRβ protein) and decreased GC-related 
transrepression of pro-inflammatory genes [11, 12]. Tan-
tisara and co-workers recently identified variations in the 
GLCCI1 gene as a factor associated with responsiveness 
to inhaled GC in asthmatic patients, and van den Berge 
et al. [7, 20] could reproduce these findings in patients with 
COPD.
Although little is known with regard to the function of 
GLCCI1, dexamethasone-induced apoptosis of immune 
cells might be one of the mechanisms influenced by 
rs37972 [7, 21]. As GC-mediated apoptosis is an impor-
tant mechanism via which GC modulate inflammatory pro-
cesses, we hypothesized that the GLCCI1 genotype might 
also influence the clinical response to exogenously admin-
istered GC in RA. In our prospectively studied cohort, we 
found a gender-specific association of GLCCI1 genotype 
and response to GC bridging therapy. Several studies in 
RA report a more severe disease course in women with 
less beneficial effects of (combination) DMARD therapy 
and of biologic agents [22–24]. The worldwide QUEST-
RA study suggests that these differences might be based 
on a different composition of the DAS by its individual 
measures in male and female patients (i.e., higher DAS in 
women at similar numbers of swollen joints) [25]. In our 
study, however, also the relative improvement in SJC, as 
the most objective individual measure of the DAS, was not 
associated with GLCCI1 genotype in female patients. This 
suggests a true gender-specific effect in men, although the 
exact mechanism remains to be elucidated. Of note, gene–
gender interactions are known in a variety of clinical disor-
ders [26].
Furthermore, carriers of minor alleles associated with 
decreased GC sensitivity (ER22/23EK, 9β, and GLCCI1) 
had higher DAS at baseline. This implies that GR and 
GLCCI1 gene polymorphisms might also be involved in 
modulation of effects of endogenously produced cortisol, 
herewith influencing the immunosuppressing effects of cor-
tisol. This might be true in particular for RA, since RA is 
characterized by relatively low cortisol levels, which are 
not in proportion with the degree of inflammation in these 
patients. This increases the importance of GC sensitivity 
for endogenously produced cortisol [27]. We cannot fully 
exclude the possibility that differences in endogenous cor-
tisol levels influenced the disease activity scores at base-
line, although we did not find a correlation between basal 
(08AM) salivary cortisol levels and DAS in a subset of 
our patients (N = 49) in whom basal salivary cortisol was 
measured as part of another substudy (data not shown).
Although the exploring character of this study under-
scores the potential of GLCCI1 genotyping as marker of GC 
sensitivity, relatively small numbers of patients have been 
Fig. 5  Relative improvement in DAS following GC bridging therapy 
in relation to GR gene polymorphisms. There were no differences in 
improvement in DAS when patients were stratified according to the 
GC-S versus GC-I model (a). Male patients (b), in general had better 
responses than female patients (c) following GC bridging therapy, but 
within group analyses of men and women did not show differences 
in relative decrease in DAS according to GR genotype. Patients who 
were homozygous carrier of the wild-type allele for all four studied 
GR polymorphisms are not depicted (N = 17). The bars represent the 
mean and standard error of the mean
1332 Rheumatol Int (2015) 35:1325–1333
1 3
included. Clearly, our findings require validation in other 
(larger) cohorts with (early) RA but might also incite to 
explore rs37972 functionality in other inflammatory diseases 
frequently treated with GC (e.g., polymyalgia rheumatica, 
inflammatory bowel disease). Furthermore, RA is consid-
ered to be a polygenic disease, and other polymorphisms 
are likely to be related to disease activity and/or response to 
GC treatment as has been shown for instance for FKBP5 in 
Crohn’s disease [28]. In addition to genetic variation, many 
other factors are likely to influence GC sensitivity and the 
response to endogenous cortisol and exogenously adminis-
tered GC (e.g., metabolism of GC, inflammatory status) [6].
In conclusion, we show that GLCCI1 gene variants 
might be associated with response to GC bridging therapy 
in male patients with RA. In addition, GR and GLCCI1 
gene polymorphisms may be associated with baseline 
disease activity in RA, suggesting that differences in the 
response to endogenously produced GC are also partly 
mediated via GR and GLCCI1 gene polymorphisms.
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